Sweden's Orexo to Sell Zubsolv's US Rights for $91 Million

04:55 AM EST, 12/23/2025 (MT Newswires) -- Swedish pharmaceutical company Orexo (ORX.ST) agreed to sell the full rights to its opioid use disorder drug Zubsolv in the US to Dexcel Pharma USA for $91 million. Dexcel Pharma will also pay $4 million to $5 million for the drug's inventory as well. Further, Orexo is eligible for a contingent payment of up to $16.8 million, based on the drug's net sales in 2026 and 2027. The company plans to use the proceeds to advance its development of rescue medications and to redeem its outstanding corporate bond. The deal is expected to close by Jan. 31, 2026, subject to customary conditions.